JAYPIRCA (Pirtobrutinib) is an oral kinase inhibitor specifically developed for the treatment of hematologic malignancies, such as mantle cell lymphoma. It functions by inhibiting Bruton's Tyrosine Kinase (BTK), a critical enzyme involved in the signaling pathways of B-cells, which play a key role in various B-cell malignancies, including MCL. By targeting BTK, JAYPIRCA disrupts the survival and proliferation of malignant B-cells, making it an effective option for patients with relapsed or refractory MCL.

Approved by the U.S. FDA in 2023, JAYPIRCA offers a therapeutic option for patients who have not achieved durable responses to prior lines of systemic therapy, including those who have been treated with other BTK inhibitors. This makes JAYPIRCA a valuable addition to the therapeutic armamentarium for managing challenging cases of MCL where treatment options are limited.